|
humans |
72 |
|
male |
69 |
|
female |
59 |
|
adult |
58 |
|
middle aged |
58 |
|
adiponectin |
50 |
|
obesity |
45 |
|
aged |
44 |
|
type 2 diabetes |
41 |
|
chinese |
39 |
|
risk factors |
36 |
|
body mass index |
35 |
|
medical sciences |
30 |
|
diabetes mellitus |
29 |
|
insulin resistance |
27 |
|
hong kong |
26 |
|
type 2 diabetes mellitus |
26 |
|
vitamin d |
26 |
|
blood pressure |
25 |
|
metabolic syndrome |
25 |
|
cardiovascular disease |
22 |
|
cohort studies |
22 |
|
blood glucose - metabolism |
21 |
|
cross-sectional studies |
21 |
|
diabetes |
21 |
|
animals |
20 |
|
fatty liver disease |
20 |
|
mice |
20 |
|
prevalence |
20 |
|
age factors |
19 |
|
atrial fibrillation |
19 |
|
chemicals and cas registry numbers |
19 |
|
hypertension |
19 |
|
mendelian randomization |
19 |
|
aged, 80 and over |
18 |
|
follow-up studies |
18 |
|
prospective studies |
18 |
|
sex factors |
18 |
|
enzyme-linked immunosorbent assay |
17 |
|
glucose tolerance test |
17 |
|
hong kong - epidemiology |
17 |
|
china - ethnology |
16 |
|
inflammation |
16 |
|
lipids |
16 |
|
reference values |
16 |
|
regression analysis |
16 |
|
rna, messenger - metabolism |
16 |
|
adolescent |
15 |
|
biological markers - blood |
15 |
|
cholesterol |
15 |
|
chronic hepatitis b |
15 |
|
coronary artery disease |
15 |
|
polycystic ovary syndrome |
15 |
|
predictive value of tests |
15 |
|
25-hydroxyvitamin d |
14 |
|
advanced glycation end-products |
14 |
|
aging |
14 |
|
alzheimer's disease |
14 |
|
cardiovascular diseases |
14 |
|
china |
14 |
|
covid-19 |
14 |
|
lipocalin-2 |
14 |
|
prognosis |
14 |
|
sars-cov-2 |
14 |
|
thyroid function tests |
14 |
|
adipocyte |
13 |
|
adipokine |
13 |
|
asian continental ancestry group |
13 |
|
asian continental ancestry group - genetics |
13 |
|
diabetic retinopathy |
13 |
|
disease progression |
13 |
|
genotype |
13 |
|
recurrence |
13 |
|
secondary prevention |
13 |
|
thyroid gland |
13 |
|
triglycerides - blood |
13 |
|
adiponectin - blood |
12 |
|
dysglycaemia |
12 |
|
fatty acid-binding proteins - blood |
12 |
|
insulin - blood |
12 |
|
ischemic stroke |
12 |
|
mice, inbred c57bl |
12 |
|
multivariate analysis |
12 |
|
myocardial infarction |
12 |
|
polymorphism, single nucleotide |
12 |
|
reverse transcriptase polymerase chain reaction |
12 |
|
severity of illness index |
12 |
|
blood glucose - analysis |
11 |
|
body composition - physiology |
11 |
|
c-reactive protein |
11 |
|
case-control studies |
11 |
|
cholesterol - blood |
11 |
|
gene frequency |
11 |
|
impaired glucose tolerance |
11 |
|
liver - metabolism |
11 |
|
liver fibrosis |
11 |
|
logistic models |
11 |
|
mafld (metabolic associated fatty liver disease) |
11 |
|
overweight |
11 |
|
polymorphism, genetic |
11 |
|
population based study |
11 |
|
rats |
11 |
|
retrospective studies |
11 |
|
risk factor |
11 |
|
thyroiditis |
11 |
|
time factors |
11 |
|
b-type natriuretic peptide |
10 |
|
cardiac troponin |
10 |
|
cardiovascular diseases - etiology |
10 |
|
cells, cultured |
10 |
|
double-blind method |
10 |
|
exome chip |
10 |
|
fibroblast growth factor |
10 |
|
gene |
10 |
|
genetic polymorphism |
10 |
|
glycaemia |
10 |
|
insulin - metabolism |
10 |
|
obesity - complications |
10 |
|
obstructive sleep apnea |
10 |
|
polymorphism |
10 |
|
risk prediction |
10 |
|
sglt2 inhibitors |
10 |
|
united states - epidemiology |
10 |
|
vitamin d-binding protein |
10 |
|
adipocytes - metabolism |
9 |
|
adiposity - physiology |
9 |
|
amino acid substitution |
9 |
|
asian-specific |
9 |
|
biological markers |
9 |
|
blood pressure - physiology |
9 |
|
cardiac dysfunction |
9 |
|
cardiovascular diseases - epidemiology |
9 |
|
carotid intima-media thickness |
9 |
|
china - epidemiology |
9 |
|
cholesterol, hdl - blood |
9 |
|
euthyroid sick syndromes |
9 |
|
exome-chip association analysis |
9 |
|
hypertension - blood - genetics |
9 |
|
hypoglycemic agents - therapeutic use |
9 |
|
linear models |
9 |
|
longitudinal studies |
9 |
|
metabolism |
9 |
|
molecular weight |
9 |
|
nucleoside analogues |
9 |
|
obesity - physiopathology |
9 |
|
oral glucose tolerance test |
9 |
|
osteoporosis |
9 |
|
pax4 |
9 |
|
questionnaires |
9 |
|
sex disparity |
9 |
|
young-onset ischemic stroke |
9 |
|
a-fabp |
8 |
|
adiponectin - biosynthesis - metabolism |
8 |
|
adiponectin - blood - genetics |
8 |
|
adipose tissue |
8 |
|
ampk |
8 |
|
atherosclerosis |
8 |
|
autoimmunity |
8 |
|
aβ |
8 |
|
blood pressure - genetics |
8 |
|
cardiovascular risk factors |
8 |
|
cognitive impairments |
8 |
|
ectopic acth syndrome |
8 |
|
exercise |
8 |
|
fasting |
8 |
|
fasting glucose |
8 |
|
fibrinogen |
8 |
|
gene expression regulation |
8 |
|
genetic predisposition to disease |
8 |
|
genetic variants |
8 |
|
genome-wide association studies |
8 |
|
glucose-stimulated insulin secretion |
8 |
|
hyperglycemia |
8 |
|
hyperglycemia - genetics |
8 |
|
hypertension - epidemiology |
8 |
|
immunohistochemistry |
8 |
|
insr |
8 |
|
insulin |
8 |
|
insulin resistance - genetics |
8 |
|
insulin resistance - physiology |
8 |
|
interferon beta-1b |
8 |
|
ischaemic stroke |
8 |
|
leptin |
8 |
|
magnetic resonance imaging |
8 |
|
metabolic syndrome x - complications |
8 |
|
mice, knockout |
8 |
|
normoglycemia |
8 |
|
obesity - epidemiology |
8 |
|
obesity - genetics |
8 |
|
obesity - genetics - metabolism |
8 |
|
polymorphism, single nucleotide - genetics |
8 |
|
prediction |
8 |
|
prediction model |
8 |
|
proliferative diabetic retinopathy |
8 |
|
proto-oncogene proteins c-akt - metabolism |
8 |
|
receptors, cell surface - genetics |
8 |
|
risk assessment |
8 |
|
sensitivity and specificity |
8 |
|
sex distribution |
8 |
|
sight-threatening diabetic retinopathy |
8 |
|
signal transduction |
8 |
|
single-nucleotide polymorphism |
8 |
|
thiazolidinediones - therapeutic use |
8 |
|
type 2 |
8 |
|
young adult |
8 |
|
3t3-l1 cells |
7 |
|
a(h1n1)pdm09 |
7 |
|
adipocyte fatty acid-binding protein |
7 |
|
adipocytes - metabolism - pathology |
7 |
|
adipokines |
7 |
|
adiponectin - blood - chemistry - genetics |
7 |
|
adiponectin oligomeric form |
7 |
|
age distribution |
7 |
|
age‐specific reference range |
7 |
|
alkaline phosphatase - blood |
7 |
|
anti-oxidant |
7 |
|
anti-steatosis |
7 |
|
antiviral agents - therapeutic use |
7 |
|
anti‐müllerian hormone |
7 |
|
autoantibodies |
7 |
|
automated chemiluminescence assay |
7 |
|
biomarker |
7 |
|
blood–brain barrier |
7 |
|
brain ischemia - blood - diagnosis - mortality |
7 |
|
cell line |
7 |
|
cell movement - drug effects |
7 |
|
cell survival signaling |
7 |
|
chinese women |
7 |
|
down-regulation - physiology |
7 |
|
dpp4 inhibitor |
7 |
|
endocrinology |
7 |
|
endothelial dysfunction |
7 |
|
fatty liver - pathology - surgery |
7 |
|
fib-4 |
7 |
|
fibrinogen - genetics - metabolism |
7 |
|
fibroblast growth factor 21 |
7 |
|
gene expression |
7 |
|
genetic predisposition to disease - genetics |
7 |
|
genetic variation |
7 |
|
genetic vectors |
7 |
|
glp1 receptor agonists |
7 |
|
gluconeogenesis |
7 |
|
graft rejection - blood - drug therapy - pathology |
7 |
|
graft survival - drug effects |
7 |
|
growth hormone |
7 |
|
haplotype |
7 |
|
haplotypes |
7 |
|
hepatic microcirculation |
7 |
|
hepatitis b, chronic - complications - drug therapy - pathology |
7 |
|
hepatocytes - metabolism |
7 |
|
hip fractures |
7 |
|
hypothyroidism |
7 |
|
immunosuppressive agents - therapeutic use |
7 |
|
influenza |
7 |
|
intra-abdominal fat - physiopathology |
7 |
|
jnk/c-jun signalling |
7 |
|
lamivudine |
7 |
|
liver cirrhosis |
7 |
|
liver cirrhosis - blood - metabolism - pathology - virology |
7 |
|
liver transplantation |
7 |
|
marginal graft |
7 |
|
metabolic dysfunction–associated steatohepatitis |
7 |
|
metabolic syndrome x - genetics |
7 |
|
mmp-9 |
7 |
|
mortality |
7 |
|
nephropathy |
7 |
|
nfs |
7 |
|
nutrition surveys |
7 |
|
obesity - blood - complications |
7 |
|
odds ratio |
7 |
|
pegylated interferon alfa-2a |
7 |
|
personalized medicine |
7 |
|
pioglitazone |
7 |
|
post–acute covid-19 syndrome |
7 |
|
ppar gamma - agonists - metabolism |
7 |
|
primary prevention |
7 |
|
severe |
7 |
|
sglt2 inhibitor |
7 |
|
single nucleotide polymorphism |
7 |
|
sleep apnea, obstructive - diagnosis - physiopathology |
7 |
|
stroke - blood - diagnosis - mortality |
7 |
|
subcutaneous fat, abdominal - physiopathology |
7 |
|
sustained virological response |
7 |
|
sympathetic activity |
7 |
|
sympathetic nervous system - physiopathology |
7 |
|
treatment outcome |
7 |
|
adaptor protein |
6 |
|
adaptor proteins, signal transducing - genetics - metabolism |
6 |
|
adiponectin - genetics |
6 |
|
adiponectin - metabolism |
6 |
|
adipose tissue - chemistry |
6 |
|
adrenalectomy |
6 |
|
adrenomedullin |
6 |
|
analysis of variance |
6 |
|
animal experiment |
6 |
|
asian continental ancestry group - statistics and numerical data |
6 |
|
biogenesis |
6 |
|
biological markers - blood - metabolism |
6 |
|
blotting, northern |
6 |
|
calcinosis - etiology - radiography |
6 |
|
carotid artery, common - radiography |
6 |
|
cell adhesion molecules - blood |
6 |
|
cell density |
6 |
|
cell membrane - metabolism |
6 |
|
circadian rhythm |
6 |
|
cohort profile // chinese |
6 |
|
coronary artery disease - etiology - radiography |
6 |
|
crisps |
6 |
|
diabetes mellitus, type 2 - blood - drug therapy |
6 |
|
diabetes mellitus, type 2 - diagnosis - ethnology - genetics |
6 |
|
diagnosis, differential |
6 |
|
dysglycemia |
6 |
|
endothelial function |
6 |
|
fatty liver |
6 |
|
gamma-glutamyltransferase - blood - metabolism |
6 |
|
genetic testing |
6 |
|
ggt |
6 |
|
glucose intolerance - blood - genetics |
6 |
|
glyburide - therapeutic use |
6 |
|
glycated hemoglobin a |
6 |
|
glycosylated hemoglobin a |
6 |
|
hba1c variability |
6 |
|
heart |
6 |
|
hemoglobin a, glycosylated - metabolism |
6 |
|
heterozygote |
6 |
|
homeostasis |
6 |
|
hong kong - epidemiology - ethnology |
6 |
|
hyperglycaemia |
6 |
|
hyperglycemia - complications - epidemiology |
6 |
|
hypertension - blood - enzymology - epidemiology |
6 |
|
hypertension - blood - epidemiology |
6 |
|
hypertension - blood - epidemiology - genetics |
6 |
|
hypertension - blood - ethnology - genetics - physiopathology |
6 |
|
hypertension - complications - epidemiology |
6 |
|
hypertriglyceridemia - epidemiology |
6 |
|
hypoglycemia |
6 |
|
igt |
6 |
|
immunotherapy |
6 |
|
incidence |
6 |
|
insulin sensitivity |
6 |
|
insulin-like growth factor i - analysis |
6 |
|
insulinoma |
6 |
|
interleukin-6 |
6 |
|
interleukin-6 - blood - genetics |
6 |
|
ischaemic heart disease |
6 |
|
jnk mitogen-activated protein kinases - genetics - metabolism |
6 |
|
likelihood functions |
6 |
|
linkage disequilibrium |
6 |
|
lipocalin |
6 |
|
lipoproteins - blood |
6 |
|
liver function test |
6 |
|
mass screening |
6 |
|
men |
6 |
|
metabolic syndrome x - blood - diagnosis |
6 |
|
metabolic syndrome x - blood - epidemiology - etiology |
6 |
|
metabolic syndrome x - complications - epidemiology - mortality |
6 |
|
mice, obese |
6 |
|
models, biological |
6 |
|
molecular sequence data |
6 |
|
multiple endocrine neoplasia type 2a |
6 |
|
neoplasms |
6 |
|
non-alcoholic fatty liver disease |
6 |
|
nuclear proteins - genetics |
6 |
|
paraganglioma |
6 |
|
pedigree |
6 |
|
ph domain and leucine zipper containing 1 (appl1) |
6 |
|
pharmacokinetics |
6 |
|
pharmacy and pharmacology environmental studies |
6 |
|
pheochromocytoma |
6 |
|
phosphotyrosine interaction |
6 |
|
polymorphism, restriction fragment length |
6 |
|
polysomnography |
6 |
|
postmenopause |
6 |
|
potassium channels, inwardly rectifying - genetics |
6 |
|
prediabetic state - diagnosis - ethnology - genetics |
6 |
|
proportional hazards models |
6 |
|
proteins - metabolism |
6 |
|
rage |
6 |
|
receptors, cell surface - blood |
6 |
|
receptors, immunologic - blood - drug effects |
6 |
|
scleroderma, systemic - complications - radiography |
6 |
|
sex characteristics |
6 |
|
single nucleotide |
6 |
|
single nucleotide polymorphisms |
6 |
|
soluble receptor for advanced glycation end-products |
6 |
|
soluble receptor of advanced glycation end-products |
6 |
|
somatostatin |
6 |
|
survival |
6 |
|
testosterone |
6 |
|
testosterone - blood |
6 |
|
thiazolidinedione |
6 |
|
thyroid diseases |
6 |
|
thyroidectomy - methods |
6 |
|
tnf receptor-associated factor 6 - genetics - metabolism |
6 |
|
toxicology and environmental safety |
6 |
|
ubiquitination |
6 |
|
vascular diseases - etiology - mortality |
6 |
|
γ-glutamyl transaminase |
6 |
|
abdominal fat - physiology |
5 |
|
acetylcysteine - pharmacology - therapeutic use |
5 |
|
acromegaly |
5 |
|
acyl coenzyme a - metabolism |
5 |
|
adaptor proteins, signal transducing - antagonists and inhibitors - genetics - physiology |
5 |
|
adaptor proteins, signal transducing - metabolism |
5 |
|
adenoviridae - genetics |
5 |
|
adipocyte fatty-acid-binding protein |
5 |
|
adiponectin - blood - genetics - metabolism |
5 |
|
adiponectin - deficiency - therapeutic use |
5 |
|
adiponectin and adipokine |
5 |
|
adipose tissue - drug effects - metabolism |
5 |
|
adiposity |
5 |
|
administration, inhalation |
5 |
|
adverse cardiovascular outcomes |
5 |
|
affinity chromatography |
5 |
|
aging - metabolism |
5 |
|
aldosterone synthase deficiency |
5 |
|
alkaline phosphatase |
5 |
|
allopurinol - pharmacology - therapeutic use |
5 |
|
androgen |
5 |
|
androgen deficiency |
5 |
|
anoxia - metabolism |
5 |
|
anti-mullerian hormone |
5 |
|
antioxidants - pharmacology - therapeutic use |
5 |
|
apolipoproteins |
5 |
|
autoimmune hypoglycaemia |
5 |
|
beta deposition |
5 |
|
binding, competitive |
5 |
|
blood glucose - drug effects |
5 |
|
blood pressure - drug effects |
5 |
|
blood sampling |
5 |
|
body weight - drug effects |
5 |
|
bone density - drug effects |
5 |
|
calcitonin - blood |
5 |
|
cancer |
5 |
|
cardiac function reserve |
5 |
|
cardiovascular diseases - epidemiology - etiology - metabolism |
5 |
|
carotid artery diseases - diagnosis |
5 |
|
carrier proteins - blood |
5 |
|
carrier proteins - genetics |
5 |
|
carrier proteins - metabolism |
5 |
|
cell adhesion molecules |
5 |
|
cell adhesion molecules - genetics |
5 |
|
cell aging - drug effects - physiology |
5 |
|
cell cycle proteins - metabolism |
5 |
|
cell proliferation - drug effects |
5 |
|
child |
5 |
|
cholesterol, ldl - blood |
5 |
|
continuous glucose monitoring |
5 |
|
coronary heart disease |
5 |
|
dentate gyrus |
5 |
|
dexamethasone |
5 |
|
dexamethasone - pharmacology |
5 |
|
diabetes complications - drug therapy - metabolism - pathology - physiopathology |
5 |
|
diabetes mellitus - blood - drug therapy - epidemiology |
5 |
|
diabetes mellitus - epidemiology |
5 |
|
diabetes mellitus, type 2 - blood - drug therapy - metabolism |
5 |
|
diabetes mellitus, type 2 - enzymology |
5 |
|
diabetes mellitus, type 2 - epidemiology |
5 |
|
diabetic cardiomyopathy |
5 |
|
diacylglycerol |
5 |
|
diagnosis |
5 |
|
diastolic function |
5 |
|
dietary fats - administration & dosage |
5 |
|
disease association |
5 |
|
disease models, animal |
5 |
|
dose-response relationship, drug |
5 |
|
drug therapy, combination |
5 |
|
dyslipidemia |
5 |
|
dyslipidemias - physiopathology |
5 |
|
elasticity imaging techniques |
5 |
|
elbasvir |
5 |
|
elisa |
5 |
|
endoscopic ultrasound |
5 |
|
endothelial cells - drug effects - metabolism - physiology |
5 |
|
endothelial nitric oxide synthase/nitric oxide (enos/no) pathway |
5 |
|
endothelin-1 - metabolism |
5 |
|
endothelium, vascular - drug effects - metabolism - physiopathology |
5 |
|
epidemiology |
5 |
|
escherichia coli - genetics |
5 |
|
exercise echocardiography |
5 |
|
exercise responsiveness |
5 |
|
f11 receptor |
5 |
|
family history |
5 |
|
fatty acid-binding proteins - physiology |
5 |
|
fatty acids, nonesterified - blood |
5 |
|
fatty-acid-binding proteins |
5 |
|
fibrinolytic agents - pharmacology - therapeutic use |
5 |
|
fibrosis |
5 |
|
gene knockdown techniques |
5 |
|
gene polymorphism |
5 |
|
genetic screening |
5 |
|
glucocorticoid |
5 |
|
glucose - biosynthesis - metabolism |
5 |
|
glucose - metabolism |
5 |
|
glucose dysregulation |
5 |
|
glycosylation |
5 |
|
grazoprevir |
5 |
|
growth hormone - blood |
5 |
|
growth hormone - blood - metabolism |
5 |
|
gut microbiota |
5 |
|
hemoglobin a, glycosylated - analysis |
5 |
|
hepatocytes - enzymology |
5 |
|
humdisease |
5 |
|
hyperglycemia - diagnosis |
5 |
|
hyperglycemia - physiopathology |
5 |
|
hypertension - ethnology - genetics |
5 |
|
hypertension - genetics - physiopathology |
5 |
|
hypertension - physiopathology |
5 |
|
hypoaldosteronism |
5 |
|
hypoglycemic agents - pharmacology - therapeutic use |
5 |
|
hypophosphatemia - etiology |
5 |
|
hypothalamus |
5 |
|
hypothalamus - drug effects - metabolism |
5 |
|
hypoxia |
5 |
|
in situ hybridization |
5 |
|
inflammation - immunology - metabolism |
5 |
|
insulin receptor autoantibodies |
5 |
|
insulin-resistance |
5 |
|
interaction profiling |
5 |
|
ionization time of flight mass spectrometry |
5 |
|
lipidomic study |
5 |
|
lipids - blood |
5 |
|
liquid chromatography-tan-dem mass spectrometry |
5 |
|
liver - drug effects - injuries - metabolism |
5 |
|
liver glycogen - metabolism |
5 |
|
liver injury |
5 |
|
lung - physiopathology |
5 |
|
lyso-phosphatidylcholine |
5 |
|
macrophages |
5 |
|
macrophages - metabolism |
5 |
|
matrix-assisted laser desorption |
5 |
|
metabolic syndrome x - blood |
5 |
|
metabolic syndrome x - complications - physiopathology |
5 |
|
mice, nude |
5 |
|
microvascular complications |
5 |
|
mitochondria |
5 |
|
mitochondrial proteins - genetics - metabolism |
5 |
|
multiple endocrine neoplasia |
5 |
|
multiple endocrine neoplasia type 2a - genetics - surgery |
5 |
|
mutagenesis, site-directed |
5 |
|
mutation, missense |
5 |
|
myocardial ischaemia/reperfusion |
5 |
|
nerve tissue proteins - metabolism |
5 |
|
nitric oxide - biosynthesis |
5 |
|
nitric oxide - metabolism |
5 |
|
non‐invasive |
5 |
|
obesity - blood |
5 |
|
obesity - blood - diagnosis |
5 |
|
obesity - blood - metabolism |
5 |
|
obesity - ethnology - genetics |
5 |
|
octreotide - therapeutic use |
5 |
|
oncogene proteins - blood |
5 |
|
outcome |
5 |
|
oxidative stress |
5 |
|
paraventricular hypothalamic nucleus - drug effects - metabolism |
5 |
|
periventricular nucleus |
5 |
|
phosphorylation - drug effects |
5 |
|
plasminogen activator inhibitor 1 - biosynthesis |
5 |
|
plasminogen activator inhibitor 1 - blood - genetics - metabolism |
5 |
|
possible involvement |
5 |
|
protein binding |
5 |
|
protein interaction mapping - methods |
5 |
|
proto-oncogene proteins - blood |
5 |
|
proto-oncogene proteins c-ret |
5 |
|
psychiatric status rating scales |
5 |
|
radio frequency ablation |
5 |
|
rats, sprague-dawley |
5 |
|
reactive oxygen species - metabolism |
5 |
|
recombinant proteins - genetics - metabolism |
5 |
|
recombinant proteins - metabolism |
5 |
|
resistin - genetics |
5 |
|
respiratory diseases |
5 |
|
rna interference |
5 |
|
rosiglitazone |
5 |
|
salt-wasting |
5 |
|
score |
5 |
|
serpin e2 |
5 |
|
serpins - blood - metabolism |
5 |
|
sex |
5 |
|
signal transduction - drug effects |
5 |
|
signaling |
5 |
|
sirtuin 1 |
5 |
|
sirtuin 3 |
5 |
|
sirtuins - genetics - metabolism |
5 |
|
sleep apnea syndromes - complications - physiopathology |
5 |
|
somatostatin - genetics |
5 |
|
stem cells - drug effects - metabolism - physiology |
5 |
|
succinate dehydrogenase |
5 |
|
sulfonylurea compounds - pharmacology - therapeutic use |
5 |
|
thiazolidinediones - pharmacology - therapeutic use |
5 |
|
thiazolidinediones - toxicity |
5 |
|
thrombotic dieases |
5 |
|
thyroid neoplasms |
5 |
|
thyroid neoplasms - genetics - prevention and control - surgery |
5 |
|
thyroidectomy |
5 |
|
tomography, x-ray computed |
5 |
|
transcription factor ap-1 - genetics - metabolism |
5 |
|
transduction, genetic |
5 |
|
triacylglycerol |
5 |
|
type b insulin resistance |
5 |
|
uncoupling protein 2 |
5 |
|
vitamin a |
5 |
|
vitamin c |
5 |
|
vitamin e |
5 |
|
waist-hip ratio |
5 |
|
2022 who classification |
4 |
|
28 inflammation in type 2 diabetes |
4 |
|
abbreviated metal test |
4 |
|
aberrant splicing |
4 |
|
acromegaly - blood - drug therapy |
4 |
|
acth precursor |
4 |
|
acth syndrome, ectopic - complications - diagnosis |
4 |
|
active transport, cell nucleus - drug effects |
4 |
|
acute disease |
4 |
|
adam questionnaire |
4 |
|
adaptor proteins, signal transducing |
4 |
|
adipokines - blood |
4 |
|
adipokines - metabolism - pharmacology |
4 |
|
adiponectin - chemistry |
4 |
|
adiponectin - deficiency - hysiology - therapeutic use |
4 |
|
adiponectin - genetics - pharmacology |
4 |
|
adiponectin - pharmacology |
4 |
|
adiponectin receptor |
4 |
|
adipopharmacology |
4 |
|
adipose tissue - metabolism |
4 |
|
adipose tissue, brown - metabolism |
4 |
|
adrenal gland neoplasms - complications |
4 |
|
adrenocorticotropic hormone - analysis |
4 |
|
afabp |
4 |
|
aging - blood |
4 |
|
albuminuria - physiopathology |
4 |
|
alkaline phosphatase - metabolism |
4 |
|
alleles |
4 |
|
alzheimers disease assessment scale cognitive subscale |
4 |
|
alzheimer’s disease |
4 |
|
amino acid sequence |
4 |
|
amlodipine |
4 |
|
amlodipine - pharmacology - therapeutic use |
4 |
|
amp-activated protein kinases |
4 |
|
amp-activated protein kinases - metabolism |
4 |
|
amyloid beta protein |
4 |
|
androgens - blood - deficiency |
4 |
|
andropause |
4 |
|
angiogenesis |
4 |
|
angiopoietin-like proteins |
4 |
|
angiopoietins |
4 |
|
anthropometry - methods |
4 |
|
anti-diabetic agents |
4 |
|
anti-hypertensive |
4 |
|
anti-obesity agents - therapeutic use |
4 |
|
anti-obesity drugs |
4 |
|
anticholesteremic agents - pharmacology - therapeutic use |
4 |
|
antihypertensive agent |
4 |
|
antihypertensive agents - pharmacology - therapeutic use |
4 |
|
antioxidants - therapeutic use |
4 |
|
anxiety - psychology |
4 |
|
apolipoprotein e polymorphism |
4 |
|
apolipoproteins - blood |
4 |
|
apolipoproteins a - genetics |
4 |
|
apoptosis - drug effects |
4 |
|
apoptosis - drug effects - physiology |
4 |
|
appl1 |
4 |
|
asian continental ancestry group - statistics & numerical data |
4 |
|
atorvastatin |
4 |
|
autophagy |
4 |
|
bariatric surgery - mortality |
4 |
|
base sequence |
4 |
|
beta catenin - metabolism |
4 |
|
beta-trace protein |
4 |
|
biological availability |
4 |
|
blood proteins - physiology |
4 |
|
blood vessels - drug effects - metabolism |
4 |
|
body weight |
4 |
|
bone metastases |
4 |
|
bone neoplasms - complications - diagnosis |
4 |
|
bone neoplasms - secondary |
4 |
|
brachial artery - physiology - ultrasonography |
4 |
|
breast cancer |
4 |
|
breast neoplasms - metabolism - pathology - therapy |
4 |
|
breathing exercises |
4 |
|
c-reactive protein - biosynthesis |
4 |
|
calcium - diagnostic use |
4 |
|
cardiovascular diseases - blood - diagnosis - ethnology |
4 |
|
cardiovascular diseases - blood - epidemiology - etiology |
4 |
|
cardiovascular diseases - blood - epidemiology - etiology - physiopathology |
4 |
|
cardiovascular diseases - epidemiology - ethnology |
4 |
|
cardiovascular diseases - metabolism - prevention and control |
4 |
|
cattle |
4 |
|
cell cycle - drug effects |
4 |
|
cell line, tumor |
4 |
|
cell nucleus - drug effects - metabolism |
4 |
|
chinese men |
4 |
|
clinical trials |
4 |
|
confidence intervals |
4 |
|
continuous positive airway pressure |
4 |
|
coronary artery disease - blood - complications - drug therapy |
4 |
|
covid‐19 |
4 |
|
cross-cultural comparison |
4 |
|
cross-over studies |
4 |
|
culture media - chemistry - pharmacology |
4 |
|
cushing syndrome - etiology |
4 |
|
cushing’s syndrome |
4 |
|
cyclin d1 - metabolism |
4 |
|
delayed-action preparations |
4 |
|
depression - psychology |
4 |
|
diabetes complications |
4 |
|
diabetes mellitus - drug therapy |
4 |
|
diabetes mellitus type 1 |
4 |
|
diabetes mellitus, experimental - complications - enzymology - physiopathology |
4 |
|
diabetes mellitus, experimental - drug therapy - metabolism |
4 |
|
diabetes mellitus, type 2 - blood - complications |
4 |
|
diabetes mellitus, type 2 - blood - drug therapy - enzymology |
4 |
|
diabetes mellitus, type 2 - blood - pathology |
4 |
|
diabetes mellitus, type 2 - genetics |
4 |
|
diabetes mellitus, type 2 - prevention & control |
4 |
|
diabetic complication |
4 |
|
dietary fats - administration & dosage - pharmacology |
4 |
|
dietary fats - metabolism |
4 |
|
dietary patterns |
4 |
|
dna primers |
4 |
|
drug combinations |
4 |
|
dyslipidaemia |
4 |
|
echocardiography |
4 |
|
endothelial progenitor cells |
4 |
|
endothelium, vascular - cytology - metabolism |
4 |
|
endothelium, vascular - drug effects - enzymology - physiology |
4 |
|
endothelium, vascular - drug effects - metabolism - physiology |
4 |
|
endothelium, vascular - drug effects - pathology |
4 |
|
endothelium, vascular - drug effects - physiology |
4 |
|
endothelium, vascular - metabolism |
4 |
|
energy metabolism |
4 |
|
energy metabolism - drug effects |
4 |
|
enzyme activation - drug effects |
4 |
|
enzyme inhibitors - therapeutic use |
4 |
|
enzyme linked immunosorbent assay |
4 |
|
epstein- barr virus |
4 |
|
ets-domain protein elk-1 - biosynthesis |
4 |
|
european continental ancestry group |
4 |
|
european continental ancestry group - statistics & numerical data |
4 |
|
exercise therapy |
4 |
|
extracellular signal-regulated map kinases - antagonists & inhibitors - metabolism |
4 |
|
fatty acids - metabolism |
4 |
|
fatty liver - surgery |
4 |
|
feeding behavior - drug effects |
4 |
|
ferritin |
4 |
|
fetal blood |
4 |
|
fibroblast growth factor 2 - pharmacology |
4 |
|
fibroblast growth factors - metabolism |
4 |
|
forearm - abnormalities |
4 |
|
free fatty acids |
4 |
|
gastric balloon |
4 |
|
gastric bypass - statistics & numerical data |
4 |
|
gastroplasty - statistics & numerical data |
4 |
|
gene delivery |
4 |
|
gene expression regulation - physiology |
4 |
|
gene therapy - methods |
4 |
|
giant cell tumor of bone - complications - diagnosis |
4 |
|
gitelman syndrome |
4 |
|
glucokinase - genetics |
4 |
|
glucose intolerance - complications - physiopathology |
4 |
|
glucose intolerance - genetics - metabolism |
4 |
|
glucose transport proteins, facilitative - biosynthesis |
4 |
|
glucose transporter type 2 |
4 |
|
glycemic index |
4 |
|
glycogen synthase kinase 3 - antagonists & inhibitors - metabolism |
4 |
|
glycogenic hepatopathy |
4 |
|
glycoproteins - blood |
4 |
|
guidelines |
4 |
|
health knowledge, attitudes, practice |
4 |
|
health status |
4 |
|
heart failure |
4 |
|
heart rate |
4 |
|
hepatic stellate cells |
4 |
|
hepatic veins |
4 |
|
heptanoic acids - pharmacology - therapeutic use |
4 |
|
herpesvirus 4, human - isolation & purification |
4 |
|
high-fat-diet-induced obesity |
4 |
|
hospitalization |
4 |
|
hypercholesterolemia - blood - ethnology |
4 |
|
hyperlipidemias - drug therapy |
4 |
|
hyperparathyroidism - complications - diagnosis |
4 |
|
hypertension - blood - complications - drug therapy |
4 |
|
hypertension - blood - complications - epidemiology - etiology - physiopathology |
4 |
|
hypertension - physiopathology - psychology - therapy - urine |
4 |
|
hypertriglyceridemia - blood - complications |
4 |
|
hypogonadism - diagnosis - ethnology |
4 |
|
hypoxia-inducible factor 1, alpha subunit - genetics - metabolism |
4 |
|
insulin - pharmacology |
4 |
|
insulin-independent |
4 |
|
intercellular signaling peptides and proteins |
4 |
|
iron |
4 |
|
isometric contraction - drug effects - physiology |
4 |
|
jnk |
4 |
|
jnk mitogen-activated protein kinases - metabolism |
4 |
|
kupffer cells |
4 |
|
lactones - therapeutic use |
4 |
|
ldlr |
4 |
|
leptin - blood |
4 |
|
lipase - blood |
4 |
|
lipase inhibitor |
4 |
|
lipid metabolism - drug effects |
4 |
|
lipoproteins, hdl - blood |
4 |
|
liver |
4 |
|
liver - drug effects - metabolism - physiopathology |
4 |
|
liver - pathology |
4 |
|
liver function tests |
4 |
|
liver sinusoidal endothelial cells |
4 |
|
longitudinal cardiac change |
4 |
|
lysine - chemistry |
4 |
|
major adverse cardiovascular events |
4 |
|
map kinase |
4 |
|
map kinase kinase kinases - antagonists & inhibitors - metabolism |
4 |
|
mediterranean diet |
4 |
|
metabolic syndrome x - blood - complications - epidemiology - physiopathology |
4 |
|
metabolic syndrome x - blood - etiology |
4 |
|
metabolic syndrome x - complications - epidemiology |
4 |
|
metabolic syndrome x - metabolism |
4 |
|
metformin |
4 |
|
mitochondria - drug effects - metabolism |
4 |
|
motor activity - drug effects |
4 |
|
multienzyme complexes - genetics - metabolism |
4 |
|
multiple lowdose streptozotocin-induced diabetes |
4 |
|
muscle, skeletal - drug effects - enzymology - physiopathology |
4 |
|
mutation |
4 |
|
nafld |
4 |
|
nafld liver fat score |
4 |
|
nasal continuous positive airway pressure |
4 |
|
nasopharyngeal carcinoma |
4 |
|
nasopharyngeal neoplasms - complications - diagnosis |
4 |
|
neovascularization |
4 |
|
neovascularization, physiologic - physiology |
4 |
|
neuroinflammation |
4 |
|
nhanes iii |
4 |
|
nitric oxide synthase type iii - drug effects - metabolism |
4 |
|
nitric oxide synthase type iii - genetics |
4 |
|
nlrp3 |
4 |
|
non-alcoholic steatohepatitis |
4 |
|
non-functioning pituitary neuroendocrine tumours |
4 |
|
obesity - surgery |
4 |
|
obstructive sleep apnoea |
4 |
|
oral antidiabetic agent |
4 |
|
orlistat |
4 |
|
osteitis deformans - blood - diagnosis - pathology - therapy |
4 |
|
osteitis deformans - diagnosis |
4 |
|
osteomalacia - etiology |
4 |
|
osteosclerosis - diagnosis |
4 |
|
oxygen - metabolism |
4 |
|
pancreatic tumor |
4 |
|
parathyroidectomy |
4 |
|
peptide fragments - blood |
4 |
|
pigment epithelium derived factor |
4 |
|
pitnet classification |
4 |
|
pituitary adenoma |
4 |
|
polymerase chain reaction |
4 |
|
polysomnography - methods |
4 |
|
postprandial lipemia |
4 |
|
postprandial period |
4 |
|
postprandial period - drug effects |
4 |
|
pre-diabetes |
4 |
|
pre-pregnancy |
4 |
|
prediabetes |
4 |
|
pregnancy |
4 |
|
preoperative care |
4 |
|
promoter regions, genetic |
4 |
|
protein blood level |
4 |
|
protein processing, post-translational |
4 |
|
protein structure, tertiary |
4 |
|
protein-serine-threonine kinases - genetics - metabolism |
4 |
|
pyrroles - pharmacology - therapeutic use |
4 |
|
qigong |
4 |
|
raf kinases - antagonists & inhibitors - metabolism |
4 |
|
randomised controlled trial |
4 |
|
receptors, adiponectin |
4 |
|
receptors, adiponectin - metabolism |
4 |
|
recombinant fusion proteins - metabolism |
4 |
|
recombinant proteins - administration & dosage - pharmacology |
4 |
|
remnant-like lipoproteins |
4 |
|
renin - blood |
4 |
|
reproducibility of results |
4 |
|
serum response factor - metabolism |
4 |
|
sibutramine |
4 |
|
slc12a3 |
4 |
|
sleep apnea, obstructive - blood - diagnosis |
4 |
|
sleep apnea, obstructive - metabolism - therapy |
4 |
|
smoking |
4 |
|
sodium glucose co-transporter 2 inhibitors |
4 |
|
sodium–glucose co-transporter type 2 inhibitors |
4 |
|
soft tissue neoplasms - complications - diagnosis |
4 |
|
somatostatin - analogs & derivatives |
4 |
|
statins |
4 |
|
stem cells - metabolism |
4 |
|
tgfβ1 |
4 |
|
thiazolidinediones - pharmacology |
4 |
|
transcription factors |
4 |
|
transfection |
4 |
|
transferrin saturation |
4 |
|
triglyceride |
4 |
|
triglyceride-rich lipoprotein remnants |
4 |
|
umbilical veins |
4 |
|
united states |
4 |
|
up-regulation - drug effects |
4 |
|
validation studies |
4 |
|
vascular diseases - physiopathology - prevention & control |
4 |
|
vascular endothelial growth factor a - pharmacology |
4 |
|
vascular homeostasis |
4 |
|
vasculature |
4 |
|
vasodilation - drug effects - physiology |
4 |
|
vitamin d - therapeutic use |
4 |
|
waist circumference |
4 |
|
weight loss |
4 |
|
weight loss - physiology |
4 |
|
xenograft model antitumor assays - methods |
4 |
|
yolk sac tumor |
4 |
|
3t3 cells |
3 |
|
absorptiometry, photon |
3 |
|
acromegaly - blood |
3 |
|
acromegaly - blood - surgery |
3 |
|
acromegaly - complications - drug therapy - pathology |
3 |
|
acromegaly - drug therapy |
3 |
|
active transport, cell nucleus |
3 |
|
adenoma - complications - secretion - surgery |
3 |
|
adenoma - radionuclide imaging - surgery - ultrasonography |
3 |
|
adipocyte fatty acid binding protein |
3 |
|
adipocytes - physiology |
3 |
|
adipogenesis |
3 |
|
adiponectin - chemistry - genetics - metabolism - secretion |
3 |
|
adiponectin - pharmacology - physiology |
3 |
|
adiponectin - physiology |
3 |
|
adrenal gland neoplasms - complications - diagnosis - surgery |
3 |
|
adrenal insufficiency - drug therapy - etiology |
3 |
|
adrenalectomy - adverse effects |
3 |
|
adrenocortical insufficiency. |
3 |
|
advanced glycation end-products (ages) |
3 |
|
aerosols |
3 |
|
age of onset |
3 |
|
ageing male |
3 |
|
alcohol drinking - metabolism |
3 |
|
aldehyde reductase - antagonists & inhibitors - genetics - metabolism |
3 |
|
aldehyde reductase - deficiency - genetics |
3 |
|
aldehyde reductase - metabolism |
3 |
|
aldose reductase gene |
3 |
|
alpha 2 macroglobulin |
3 |
|
alpha-macroglobulins - physiology |
3 |
|
alzheimer disease - blood |
3 |
|
alzheimer disease - blood - diagnosis - ethnology |
3 |
|
alzheimer disease - genetics - physiopathology |
3 |
|
amino acid motifs - physiology |
3 |
|
andrology |
3 |
|
angiopoietins - genetics - metabolism |
3 |
|
animal cell |
3 |
|
anticholesteremic agents - therapeutic use |
3 |
|
antigens, cd - genetics - metabolism |
3 |
|
antineoplastic agents - therapeutic use |
3 |
|
antineoplastic agents, hormonal - therapeutic use |
3 |
|
antiobesity drugs |
3 |
|
antioxidants - chemistry - pharmacology |
3 |
|
anxiety |
3 |
|
aorta - cytology - metabolism |
3 |
|
aorta, thoracic - drug effects - metabolism |
3 |
|
apolipoprotein a-i - analysis |
3 |
|
apolipoprotein e |
3 |
|
apolipoprotein e4 - genetics |
3 |
|
apolipoprotein(a) |
3 |
|
apolipoproteins a - analysis |
3 |
|
apoptosis |
3 |
|
ar, aldose reductase |
3 |
|
ari, ar inhibitor |
3 |
|
asian continental ancestry group - ethnology |
3 |
|
asians |
3 |
|
association |
3 |
|
asthma - drug therapy |
3 |
|
astragalus extract |
3 |
|
beclomethasone - administration & dosage - adverse effects |
3 |
|
benzothiazoles |
3 |
|
berberine - pharmacology - therapeutic use |
3 |
|
beta-2 microglobulin |
3 |
|
biological monitoring |
3 |
|
blood proteins - chemistry - metabolism |
3 |
|
blotting, western |
3 |
|
body composition |
3 |
|
body weight - physiology |
3 |
|
bone density |
3 |
|
bone marrow |
3 |
|
brachial artery - physiopathology |
3 |
|
brain diseases - complications |
3 |
|
breast neoplasms - etiology - metabolism - pathology |
3 |
|
bronchodilator agents - administration & dosage - adverse effects |
3 |
|
budesonide |
3 |
|
c-peptide - blood |
3 |
|
c-reactive protein - metabolism |
3 |
|
calorie restriction |
3 |
|
calycosin |
3 |
|
carbohydrate metabolism |
3 |
|
cardiovascular diseases - blood - ethnology |
3 |
|
cardiovascular diseases - blood - ethnology - genetics |
3 |
|
cardiovascular events |
3 |
|
cardiovascular risk |
3 |
|
carotid artery |
3 |
|
carotid plaque |
3 |
|
cell adhesion |
3 |
|
cell adhesion - drug effects |
3 |
|
cell adhesion molecules - genetics - metabolism |
3 |
|
cell culture techniques |
3 |
|
cell differentiation |
3 |
|
cell fractionation |
3 |
|
cell isolation |
3 |
|
cell nucleus - metabolism |
3 |
|
cell proliferation |
3 |
|
central obesity |
3 |
|
cephalometry |
3 |
|
chemokine ccl2 - genetics - metabolism |
3 |
|
child, preschool |
3 |
|
cholesterol, hdl/blood |
3 |
|
choristoma-complications |
3 |
|
chromatography, affinity |
3 |
|
chromatography, high pressure liquid |
3 |
|
chromatography, liquid |
3 |
|
clarity |
3 |
|
codon, nonsense |
3 |
|
cognition - physiology |
3 |
|
cognition disorders - blood |
3 |
|
cognition disorders - genetics - physiopathology |
3 |
|
collagen type iv - biosynthesis - physiology |
3 |
|
community health centers - trends |
3 |
|
comorbidity |
3 |
|
control |
3 |
|
cost-benefit analysis |
3 |
|
cox regression |
3 |
|
cpap therapy |
3 |
|
cpg islands |
3 |
|
culture media - chemistry |
3 |
|
cyclic amp - metabolism |
3 |
|
cycloheximide |
3 |
|
depression |
3 |
|
dhe, dihydroethidium |
3 |
|
diabetes incidence |
3 |
|
diabetes insipidus - complications |
3 |
|
diabetes mellitus - blood - diet therapy - drug therapy - epidemiology - ethnology |
3 |
|
diabetes mellitus - diagnosis - epidemiology |
3 |
|
diabetes mellitus - epidemiology - ethnology - therapy |
3 |
|
diabetes mellitus - metabolism |
3 |
|
diabetes mellitus, experimental - genetics - physiopathology |
3 |
|
diabetes mellitus, type 1 - immunology |
3 |
|
diabetes mellitus, type 2 - blood - complications - epidemiology |
3 |
|
diabetes mellitus, type 2 - blood - diagnosis - epidemiology |
3 |
|
diabetes mellitus, type 2 - blood - physiopathology - ultrasonography |
3 |
|
diabetes-insipidus-etiology |
3 |
|
diabetic atherosclerosis |
3 |
|
diabetic glomerulopathy |
3 |
|
diabetic nephropathies - physiopathology |
3 |
|
diabetic nephropathy |
3 |
|
diet |
3 |
|
diet therapy |
3 |
|
differentiation |
3 |
|
dimerization |
3 |
|
diseases in twins - genetics |
3 |
|
dna damage |
3 |
|
dna methylation |
3 |
|
dna mutational analysis - methods |
3 |
|
drug tolerance |
3 |
|
dyslipidemias - blood |
3 |
|
editorial policies |
3 |
|
electrophoresis, gel, two-dimensional |
3 |
|
endothelial cells - drug effects - enzymology |
3 |
|
endothelium |
3 |
|
endothelium, vascular - cytology - physiopathology - ultrasonography |
3 |
|
enzyme activation |
3 |
|
enzyme inhibitors - metabolism |
3 |
|
enzyme inhibitors - pharmacology |
3 |
|
epigenesis, genetic |
3 |
|
erk, extracellular signal-regulated kinase-1 |
3 |
|
erratum |
3 |
|
error |
3 |
|
escherichia coli - metabolism |
3 |
|
ethanol |
3 |
|
extracellular fluid - metabolism |
3 |
|
extracellular matrix proteins - genetics |
3 |
|
fatty acids - blood |
3 |
|
fatty acids, nonesterified - metabolism |
3 |
|
fatty liver - drug therapy |
3 |
|
fatty liver - etiology - physiopathology - therapy |
3 |
|
fibrinogen - analysis |
3 |
|
fibroblast growth factor-21 |
3 |
|
fibroblast growth factors - biosynthesis |
3 |
|
fibroblast growth factors - blood |
3 |
|
frameshift mutation |
3 |
|
fructose - metabolism |
3 |
|
fto |
3 |
|
gait |
3 |
|
gait speed |
3 |
|
gender difference |
3 |
|
gene expression - drug effects |
3 |
|
gene expression regulation, neoplastic |
3 |
|
genes, reporter |
3 |
|
genetic association studies |
3 |
|
genetic variation - genetics |
3 |
|
geriatric assessment |
3 |
|
germ-line mutation |
3 |
|
gestational diabetes mellitus |
3 |
|
glucose intolerance |
3 |
|
glucose intolerance - blood - diagnosis - epidemiology |
3 |
|
glucose intolerance - epidemiology |
3 |
|
glucose intolerance - genetics |
3 |
|
glutathione - metabolism |
3 |
|
glycated haemoglobin a |
3 |
|
glycogen synthase kinase 3 - physiology |
3 |
|
glycosylation end products, advanced - pharmacology |
3 |
|
glycosylation end products, advanced - physiology |
3 |
|
growth disorders - blood - drug therapy |
3 |
|
growth hormone - blood - deficiency |
3 |
|
growth hormone - metabolism |
3 |
|
growth hormone - secretion |
3 |
|
growth hormone-releasing hormone - administration & dosage - therapeutic use |
3 |
|
haemoglobin a1c |
3 |
|
hba1c |
3 |
|
hdl-cholesterol |
3 |
|
hepatic steatosis |
3 |
|
hla antigens - analysis - genetics |
3 |
|
hla-d antigens - genetics |
3 |
|
hla-dr antigens - genetics |
3 |
|
hla-dr serological subtypes |
3 |
|
hla-dr3 antigen |
3 |
|
hong kong - ethnology |
3 |
|
hormone |
3 |
|
human growth hormone - blood |
3 |
|
human growth hormone - metabolism |
3 |
|
human growth hormone - secretion |
3 |
|
hydrocortisone - therapeutic use |
3 |
|
hyperaldosteronism - diagnosis - surgery |
3 |
|
hyperglycemia - blood - diagnosis - epidemiology |
3 |
|
hyperglycemia - drug therapy - metabolism |
3 |
|
hyperparathyroidism, primary - etiology |
3 |
|
hyperplasia |
3 |
|
hypertension - epidemiology - etiology |
3 |
|
hypertriglyceridaemia |
3 |
|
hypertriglyceridemia |
3 |
|
hypoglycaemia |
3 |
|
hypoglycemic agents - administration and dosage - therapeutic use |
3 |
|
hypothyroidism - etiology |
3 |
|
immunoglobulin enhancer binding protein |
3 |
|
inositol - metabolism |
3 |
|
insulin - administration and dosage - therapeutic use |
3 |
|
insulin-like growth factor i - blood |
3 |
|
insulinoma - diagnosis - surgery |
3 |
|
insulinoma - pathology - surgery |
3 |
|
intercellular signaling peptides and proteins - blood |
3 |
|
intercellular signaling peptides and proteins - blood - chemistry - isolation & purification |
3 |
|
intercellular signaling peptides and proteins - genetics |
3 |
|
intracranial occlusive disease |
3 |
|
intraoperative period |
3 |
|
isoelectric focusing |
3 |
|
jnk, c-jun nh2 terminal kinase |
3 |
|
kidney |
3 |
|
kidney glomerulus - cytology - pathology |
3 |
|
l-iditol 2-dehydrogenase |
3 |
|
l-iditol 2-dehydrogenase - metabolism |
3 |
|
lean mass |
3 |
|
left ventricular function |
3 |
|
lens, crystalline - metabolism |
3 |
|
likelihood ratio test |
3 |
|
lipid metabolism |
3 |
|
lipid profiles |
3 |
|
lipoprotein lipase - antagonists & inhibitors - genetics - metabolism |
3 |
|
lipoprotein(a) |
3 |
|
lipoproteins |
3 |
|
lipoproteins, ldl - blood |
3 |
|
logistic discrimination |
3 |
|
lorcaserin |
3 |
|
lymphoma, non-hodgkin - complications |
3 |
|
machine learning algorithm |
3 |
|
magnetic resonance spectroscopy |
3 |
|
mammary neoplasms, animal - metabolism - pathology |
3 |
|
mapk, mitogen-activated protein kinase |
3 |
|
mass spectrometry |
3 |
|
mass spectrometry - methods |
3 |
|
melanoma |
3 |
|
melanoma - diagnosis - secondary - surgery |
3 |
|
mesenchymal stem cells - chemistry - physiology |
3 |
|
meta-analysis |
3 |
|
metabolic outcomes |
3 |
|
metabolic syndrome x - complications - prevention & control |
3 |
|
metabolic syndrome x - diet therapy - drug therapy - epidemiology - ethnology |
3 |
|
metastasis |
3 |
|
methionine - metabolism |
3 |
|
mice, transgenic |
3 |
|
microalbuminuria |
3 |
|
mild cognitive impairment |
3 |
|
minimally invasive parathyroidectomy |
3 |
|
mncv, motor nerve conduction velocity |
3 |
|
monocytes - cytology - drug effects |
3 |
|
motor neurons - physiology |
3 |
|
multiple endocrine neoplasia type 1 - genetics |
3 |
|
multiple endocrine neoplasia type 1 - surgery |
3 |
|
muscle, skeletal - metabolism |
3 |
|
muscle, smooth, vascular - drug effects - metabolism |
3 |
|
nash |
3 |
|
neoplasms, hormone-dependent - metabolism |
3 |
|
nephritis, interstitial - complications - pathology |
3 |
|
nerve tissue proteins - genetics - metabolism |
3 |
|
nervous system - metabolism |
3 |
|
neural conduction - physiology |
3 |
|
neuropsychological tests |
3 |
|
nitric oxide |
3 |
|
nitric oxide bioavailability |
3 |
|
nitric oxide synthase type iii - metabolism |
3 |
|
non‐hodgkin's lymphoma |
3 |
|
nuclear proteins |
3 |
|
obesity - complications - metabolism |
3 |
|
obesity, morbid - blood |
3 |
|
obesity. type 2 diabetes |
3 |
|
octreotide |
3 |
|
octreotide - administration & dosage |
3 |
|
oligoribonucleotides, antisense - pharmacology |
3 |
|
osteoporosis - chemically induced |
3 |
|
paired samples |
3 |
|
pancreas |
3 |
|
pancreatic neoplasms - diagnosis - surgery |
3 |
|
pancreatic neoplasms - pathology - surgery |
3 |
|
par, poly(adp-ribose) |
3 |
|
parathyroid adenoma |
3 |
|
parathyroid neoplasms - radionuclide imaging - surgery - ultrasonography |
3 |
|
peptide mapping - methods |
3 |
|
periodicals as topic |
3 |
|
peripheral arterial disease |
3 |
|
phentermine/topiramate |
3 |
|
phosphorylation |
3 |
|
phthalazines - pharmacology |
3 |
|
pituitary |
3 |
|
pituitary neoplasms - diagnosis - secondary - surgery |
3 |
|
pituitary-gland |
3 |
|
placebos |
3 |
|
poly adenosine diphosphate ribose - metabolism |
3 |
|
polymers - metabolism |
3 |
|
polyphenols |
3 |
|
population surveillance |
3 |
|
postmenopausal |
3 |
|
postoperative complications |
3 |
|
postoperative complications - epidemiology |
3 |
|
postoperative complications - epidemiology - etiology |
3 |
|
postpartum glucose tolerance |
3 |
|
power |
3 |
|
ppar gamma - physiology |
3 |
|
practice guidelines as topic |
3 |
|
pregnancy in diabetics - epidemiology - metabolism |
3 |
|
pregnenediones - administration & dosage - adverse effects |
3 |
|
premenopause |
3 |
|
prepregnancy |
3 |
|
primary hyperparathyroidism |
3 |
|
promoter regions, genetic - genetics |
3 |
|
protease inhibitors |
3 |
|
protein processing, post-translational - drug effects |
3 |
|
protein structure, tertiary - physiology |
3 |
|
proteins - genetics |
3 |
|
proteins - metabolism - pharmacology |
3 |
|
proteome |
3 |
|
proteome - analysis |
3 |
|
proteomics |
3 |
|
proteomics - methods |
3 |
|
psychological factors |
3 |
|
quality of life |
3 |
|
radioactive iodine |
3 |
|
radioimmunoassay |
3 |
|
radiotherapy - adverse effects |
3 |
|
randomized controlled trials as topic |
3 |
|
receptor, melanocortin, type 4 - genetics - metabolism |
3 |
|
receptors, cell surface - metabolism |
3 |
|
receptors, estrogen - metabolism |
3 |
|
recombinant proteins - chemistry |
3 |
|
recombinant proteins - therapeutic use |
3 |
|
retinol-binding protein 4 |
3 |
|
risk stratification |
3 |
|
rna, messenger - analysis - biosynthesis |
3 |
|
rna, small interfering |
3 |
|
sarcopenia |
3 |
|
sella-turcica |
3 |
|
sequence alignment - methods |
3 |
|
serum albumin, bovine |
3 |
|
serum albumin, bovine - pharmacology |
3 |
|
simple |
3 |
|
skin neoplasms - pathology - surgery |
3 |
|
skull-neoplasms-complications |
3 |
|
sleep apnea syndromes - complications - drug therapy - pathology |
3 |
|
sleep apnea, obstructive - diagnosis - epidemiology - etiology |
3 |
|
sorbitol - metabolism |
3 |
|
sp1 transcription factor - physiology |
3 |
|
splenic artery |
3 |
|
statistics, nonparametric |
3 |
|
stilbenes - chemistry - pharmacology |
3 |
|
stress |
3 |
|
superoxides - metabolism |
3 |
|
sural nerve - physiopathology |
3 |
|
t-wave alternans |
3 |
|
tc99m-sestamibi scintigraphy |
3 |
|
technetium tc 99m sestamibi |
3 |
|
tgf-β 1 |
3 |
|
the metabolic syndrome |
3 |
|
thiazoles - pharmacology |
3 |
|
three-dimensional imaging |
3 |
|
thrombospondin-1 |
3 |
|
thyrotoxicosis |
3 |
|
tissue clearing |
3 |
|
total cholesterol |
3 |
|
transcription, genetic |
3 |
|
transfection - methods |
3 |
|
transforming growth factor beta - physiology |
3 |
|
transforming growth factor beta1 |
3 |
|
transgenic mouse |
3 |
|
transsphenoidal approach |
3 |
|
triglycerides |
3 |
|
triglycerides - metabolism |
3 |
|
trypsin - chemistry |
3 |
|
two-dimensional gel electrophoresis |
3 |
|
type i error |
3 |
|
type iv collagen |
3 |
|
ultrasonography |
3 |
|
urotensin ii |
3 |
|
urotensins - genetics - metabolism |
3 |
|
vascular injury |
3 |
|
vasodilation |
3 |
|
waist circumference - physiology |
3 |
|
wine - analysis |
3 |
|
糖尿(glycosuria) |
3 |
|
糖尿病(diabetes mellitus) |
3 |
|
糖尿病1型(diabetes mellitus, type 1) |
3 |
|
都市化(urbanization) |
3 |
|
香港(hong kong) |
3 |
|
5' untranslated regions - genetics |
2 |
|
5-aminolevulinate synthetase - genetics - metabolism |
2 |
|
abcd1 gene |
2 |
|
abdomen |
2 |
|
acromegaly - complications - pathology |
2 |
|
acromegaly - complications - surgery |
2 |
|
acromegaly - etiology |
2 |
|
acute leukaemia |
2 |
|
acute-phase proteins |
2 |
|
addison disease - etiology |
2 |
|
addison's disease, idiopathic |
2 |
|
adenocarcinoma - complications - secondary |
2 |
|
adenoma - diagnosis - secretion |
2 |
|
adiponectin - blood - chemistry |
2 |
|
adiponectin - chemistry - metabolism - secretion |
2 |
|
adiponectin - metabolism - physiology |
2 |
|
adipose tissue - anatomy & histology |
2 |
|
adipose tissue - cytology - metabolism |
2 |
|
adrenal cortex hormones - administration & dosage - therapeutic use |
2 |
|
adrenal gland neoplasms - complications - secondary |
2 |
|
adrenal steroids |
2 |
|
adrenoleukodystrophy |
2 |
|
adrenoleukodystrophy - genetics |
2 |
|
african continental ancestry group - statistics & numerical data |
2 |
|
aging - blood - physiology |
2 |
|
albuminuria - drug therapy |
2 |
|
albuminuria - genetics |
2 |
|
aldehyde reductase - genetics |
2 |
|
aldose reductase |
2 |
|
androgens - blood - metabolism |
2 |
|
angiotensin ii receptor antagonist |
2 |
|
angiotensin receptor antagonists |
2 |
|
anterior pituitary |
2 |
|
anthropometry |
2 |
|
anti-inflammatory agents - therapeutic use |
2 |
|
anticholesteremic agents - administration & dosage - adverse effects |
2 |
|
anticholesteremic agents - pharmacology |
2 |
|
antigens, cd36 - genetics |
2 |
|
antihypertensive agents |
2 |
|
antihypertensive therapy |
2 |
|
antilipemic agents - pharmacology - therapeutic use |
2 |
|
antioxidants - metabolism |
2 |
|
apolipoprotein (a) phenotype |
2 |
|
apolipoprotein a-i - blood |
2 |
|
apolipoproteins a - blood - genetics |
2 |
|
apolipoproteins b - analysis |
2 |
|
apolipoproteins b - blood |
2 |
|
apoprotein(a) |
2 |
|
asthma |
2 |
|
asthma - blood - drug therapy |
2 |
|
atp-binding cassette transporters - genetics - metabolism |
2 |
|
autoantibodies - analysis |
2 |
|
autoimmunity - physiology |
2 |
|
autoradiography |
2 |
|
awareness |
2 |
|
beta-thalassemia - blood - complications |
2 |
|
biocatalysis |
2 |
|
biopolymers - chemistry |
2 |
|
blood coagulation - drug effects |
2 |
|
blood glucose variations |
2 |
|
body constitution |
2 |
|
body height - drug effects |
2 |
|
bone loss |
2 |
|
bone marrow transplantation |
2 |
|
bone metabolism |
2 |
|
bone mineral density |
2 |
|
brachial artery - ultrasonography |
2 |
|
brain |
2 |
|
brain - physiology |
2 |
|
brain diseases - etiology - radiography |
2 |
|
brain edema - etiology |
2 |
|
brain hemorrhage |
2 |
|
bromocriptine - therapeutic use |
2 |
|
brown |
2 |
|
c-reactive protein - analysis - antagonists & inhibitors |
2 |
|
calcitriol - administration & dosage |
2 |
|
calcium - administration & dosage - blood |
2 |
|
calcium - urine |
2 |
|
calcium, dietary - administration & dosage |
2 |
|
carbamylation |
2 |
|
cardiometabolic disorders |
2 |
|
cardiopulmonary bypass |
2 |
|
cardiovascular diseases - prevention & control |
2 |
|
castration |
2 |
|
cavernous sinus - pathology |
2 |
|
centrifugation, density gradient |
2 |
|
cerebral cortex - metabolism |
2 |
|
cerebral hemorrhage - blood - complications |
2 |
|
cerebral infarction - blood - complications |
2 |
|
cerebrotendinous xanthomatosis |
2 |
|
cholesterol - biosynthesis - blood |
2 |
|
cholesterol blood level |
2 |
|
cholesterol ester transfer proteins |
2 |
|
cholesterol, ldl - analysis |
2 |
|
cholesteryl ester transfer protein |
2 |
|
chorionic gonadotropin - administration & dosage - pharmacology - therapeutic use |
2 |
|
chromatography, gel |
2 |
|
classification model |
2 |
|
cloning, molecular |
2 |
|
codon - genetics |
2 |
|
codon, terminator - genetics |
2 |
|
complication |
2 |
|
copper - chemistry |
2 |
|
coronary disease - metabolism - pathology |
2 |
|
corticosteroid |
2 |
|
creatinine - blood |
2 |
|
cyanate |
2 |
|
cyp27a1 |
2 |
|
cytochrome p-450 cyp27a1 |
2 |
|
ddavp |
2 |
|
decompression, surgical - methods |
2 |
|
dexamethasone - administration & dosage - pharmacology |
2 |
|
diabetes mellitus - blood - classification |
2 |
|
diabetes mellitus - blood - classification - drug therapy - immunology |
2 |
|
diabetes mellitus - economics |
2 |
|
diabetes mellitus - enzymology - genetics |
2 |
|
diabetes mellitus - epidemiology - metabolism |
2 |
|
diabetes mellitus, type 1 - blood |
2 |
|
diabetes mellitus, type 1 - epidemiology - genetics |
2 |
|
diabetes mellitus, type 2 - blood |
2 |
|
diabetes mellitus, type 2 - blood - complications - genetics |
2 |
|
diabetes mellitus, type 2 - blood - complications - physiopathology |
2 |
|
diabetes mellitus, type 2 - blood - drug therapy - physiopathology |
2 |
|
diabetes mellitus, type 2 - blood - epidemiology - genetics |
2 |
|
diabetes mellitus, type 2 - blood - immunology |
2 |
|
diabetes mellitus, type 2 - blood - physiopathology |
2 |
|
diabetes mellitus, type 2 - complications - diagnosis |
2 |
|
diabetes mellitus, type 2 - complications - physiopathology |
2 |
|
diabetes mellitus, type 2 - diagnosis - epidemiology - genetics |
2 |
|
diabetes mellitus, type 2 - drug therapy - physiopathology |
2 |
|
diabetes mellitus, type 2 - drug therapy - physiopathology - ultrasonography |
2 |
|
diabetes mellitus, type 2 - enzymology - genetics |
2 |
|
diabetes mellitus, type 2 - epidemiology - genetics |
2 |
|
diabetes mellitus, type 2 - epidemiology - metabolism - physiopathology |
2 |
|
diabetes mellitus, type 2 - metabolism - pathology |
2 |
|
diabetes mellitus, type 2 - physiopathology |
2 |
|
diabetes-insipidus-complications |
2 |
|
diabetic angiopathies |
2 |
|
diabetic diet |
2 |
|
diabetic ketoacidosis - blood - immunology |
2 |
|
diabetic nephropathies |
2 |
|
diabetic nephropathies - complications - physiopathology |
2 |
|
diabetic nephropathies - genetics |
2 |
|
diabetic nephropathies - prevention & control |
2 |
|
diabetic retinopathy - enzymology - epidemiology - genetics |
2 |
|
diagnostic criteria |
2 |
|
diet records |
2 |
|
dietary carbohydrates - administration & dosage |
2 |
|
dinucleotide repeats |
2 |
|
dna - genetics |
2 |
|
dna transposable elements - genetics |
2 |
|
dna, satellite - genetics |
2 |
|
dna-binding proteins - genetics |
2 |
|
dna-cytosine methylases |
2 |
|
dose-response relationship, radiation |
2 |
|
educational status |
2 |
|
egfr equations |
2 |
|
electrophoresis |
2 |
|
electrophoresis, polyacrylamide gel |
2 |
|
endoscopes |
2 |
|
endoscopy - methods |
2 |
|
endothelium, vascular - drug effects - physiopathology - ultrasonography |
2 |
|
endothelium, vascular - metabolism - pathology - physiology |
2 |
|
endothelium, vascular - physiology - physiopathology |
2 |
|
endothelium, vascular - physiology - ultrasonography |
2 |
|
endothelium, vascular - physiopathology |
2 |
|
energy intake |
2 |
|
environmental |
2 |
|
estradiol - blood |
2 |
|
estrogen |
2 |
|
estrogens - blood - physiology |
2 |
|
estrogens - pharmacology |
2 |
|
etidronate |
2 |
|
exons |
2 |
|
exophthalmos |
2 |
|
exophthalmos - surgery |
2 |
|
factor vii |
2 |
|
factor vii - genetics |
2 |
|
fatty acids, monounsaturated - pharmacology |
2 |
|
fatty liver - blood - complications |
2 |
|
fibrinolysis - drug effects |
2 |
|
fibroblast growth factors - analysis - blood |
2 |
|
fibrous dysplasia of bone |
2 |
|
fibrous dysplasia, polyostotic - complications - pathology |
2 |
|
fluorodeoxyglucose f18 |
2 |
|
follow up |
2 |
|
fruit |
2 |
|
functional analysis |
2 |
|
gene therapy |
2 |
|
generalized estimating equations |
2 |
|
genetic |
2 |
|
genetic linkage |
2 |
|
glomerular filtration rate - drug effects |
2 |
|
glucagon - blood |
2 |
|
glucocorticoids - pharmacology |
2 |
|
glucose - pharmacology |
2 |
|
glucose tolerance |
2 |
|
glutamate decarboxylase - immunology - metabolism |
2 |
|
glutathione transferase - metabolism - physiology |
2 |
|
glycoproteins |
2 |
|
glycosylation end products, advanced - blood |
2 |
|
glycoxidized low-density lipoprotein |
2 |
|
goals |
2 |
|
gonadal steroid hormones - physiology |
2 |
|
gonadal steroids |
2 |
|
gonadotrophins |
2 |
|
graves disease - metabolism - radiotherapy |
2 |
|
graves disease - radiotherapy |
2 |
|
graves disease - surgery |
2 |
|
graves' disease |
2 |
|
growth disorders - blood - drug therapy - etiology |
2 |
|
growth hormone - blood - drug effects |
2 |
|
growth hormone - blood - genetics |
2 |
|
growth hormone - blood - therapeutic use |
2 |
|
growth hormone releasing hormone |
2 |
|
growth hormone-releasing hormone |
2 |
|
growth hormone-releasing hormone - genetics |
2 |
|
growth hormone-releasing hormone - genetics - metabolism |
2 |
|
growth hormone-releasing hormone receptor |
2 |
|
haemorrhagic stroke |
2 |
|
health expenditures |
2 |
|
health surveys |
2 |
|
heart atria - surgery |
2 |
|
heart neoplasms - complications - diagnosis - surgery |
2 |
|
heat dissipation |
2 |
|
hepatic lipase |
2 |
|
hepatitis - blood - etiology |
2 |
|
hepatocyte nuclear factor |
2 |
|
hepatocyte nuclear factor 1 |
2 |
|
hepatocyte nuclear factor 1-alpha |
2 |
|
hepatocyte nuclear factor 1-beta |
2 |
|
hepatocyte nuclear factor 4 |
2 |
|
heptanoic acids - therapeutic use |
2 |
|
heterozygote detection |
2 |
|
histocompatibility testing |
2 |
|
hiv protease inhibitors - adverse effects - pharmacology |
2 |
|
hla antigens - analysis |
2 |
|
hla-dr3 antigen - genetics |
2 |
|
hmg coa reductase inhibitor |
2 |
|
homeostasis - physiology |
2 |
|
homocysteine |
2 |
|
homocysteine - blood |
2 |
|
hong kong chinese |
2 |
|
hormone antagonists - therapeutic use |
2 |
|
hormone replacement therapy |
2 |
|
hormones |
2 |
|
hormones - physiology |
2 |
|
hydrochlorothiazide - therapeutic use |
2 |
|
hydroxymethylglutaryl-coa reductase inhibitors |
2 |
|
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage - adverse effects |
2 |
|
hypercalciuria |
2 |
|
hypercholesterolaemia |
2 |
|
hypercholesterolemia - drug therapy |
2 |
|
hyperhomocysteinemia - blood - complications - physiopathology |
2 |
|
hyperlipidemias - chemically induced |
2 |
|
hyperlipidemias - complications - genetics |
2 |
|
hyperlipidemias - drug therapy - etiology |
2 |
|
hypernatremia-complications |
2 |
|
hyperparathyroidism - diagnosis - epidemiology - surgery |
2 |
|
hyperprolactinemia - complications - pathology |
2 |
|
hypertension - drug therapy - epidemiology - physiopathology |
2 |
|
hypertension - epidemiology - prevention & control - therapy |
2 |
|
hypertension, malignant - complications |
2 |
|
hypocalcemia |
2 |
|
hypocalcemia - drug therapy - etiology - urine |
2 |
|
hypoglycemia - drug therapy - etiology |
2 |
|
hypogonadism - drug therapy - pathology |
2 |
|
hypogonadotrophic hypogonadsm |
2 |
|
hyponatremia - etiology |
2 |
|
hypopituitarism - complications - diagnosis - etiology |
2 |
|
hypothalamic-pituitary dysfunction |
2 |
|
hypothalamo-hypophyseal system - physiopathology - radiation effects |
2 |
|
hypothalamus - chemistry - metabolism |
2 |
|
hypothalamus - metabolism |
2 |
|
hypothermia, induced |
2 |
|
hypothyroidism - blood |
2 |
|
hypothyroidism - genetics - metabolism |
2 |
|
hypothyroidism - physiopathology |
2 |
|
immunoblotting - methods |
2 |
|
independently associated |
2 |
|
indoles - pharmacology |
2 |
|
inhaled corticosteroids |
2 |
|
insertion |
2 |
|
insulin - secretion |
2 |
|
insulin - therapeutic use |
2 |
|
insulin-like growth factor i - drug effects - metabolism |
2 |
|
insulin-like growth factor-i |
2 |
|
insulin-secreting cells - immunology |
2 |
|
insulinoma - blood - diagnosis |
2 |
|
intranasal |
2 |
|
introns |
2 |
|
iodine radioisotopes - adverse effects - therapeutic use |
2 |
|
iodine radioisotopes - metabolism - therapeutic use |
2 |
|
isomerism |
2 |
|
keratitis |
2 |
|
kidney calculi - drug therapy - etiology - urine |
2 |
|
killer cells, natural - metabolism |
2 |
|
kinetics |
2 |
|
leukemia - complications |
2 |
|
leukemia, myeloid - complications - therapy |
2 |
|
leukemia-lymphoma, adult t-cell - complications - therapy |
2 |
|
lipid peroxidation |
2 |
|
lipocalins - blood |
2 |
|
lipoprotein |
2 |
|
lipoprotein (a) |
2 |
|
lipoprotein lipase |
2 |
|
lipoprotein lipase - blood |
2 |
|
lipoprotein(a) - metabolism |
2 |
|
lipoproteins, ldl - blood - drug effects |
2 |
|
lipoproteins, ldl - physiology |
2 |
|
liver cirrhosis - blood - etiology |
2 |
|
losartan - therapeutic use |
2 |
|
lovastatin - therapeutic use |
2 |
|
luminescent measurements |
2 |
|
macrophage |
2 |
|
macrophages - chemistry |
2 |
|
macrophages - cytology |
2 |
|
maturity-onset diabetes of the young |
2 |
|
menotropins - administration & dosage - pharmacology - therapeutic use |
2 |
|
metabolic syndrome x - epidemiology |
2 |
|
metabolic syndrome x - physiology |
2 |
|
metabolic variates |
2 |
|
mexican americans - statistics & numerical data |
2 |
|
mice, inbred balb c |
2 |
|
microsomal triglyceride transfer protein |
2 |
|
missing values |
2 |
|
mixed effects model |
2 |
|
molecular chaperones - metabolism - physiology |
2 |
|
molecular neuroendocrinology |
2 |
|
mri |
2 |
|
multiple endocrine neoplasia type 2a - complications |
2 |
|
muscle strength |
2 |
|
muscle strength - physiology |
2 |
|
mutation - genetics |
2 |
|
myasthenia gravis - chemically induced - complications |
2 |
|
myasthenia gravis - classification - genetics - immunology |
2 |
|
myeloperoxidase |
2 |
|
myocardial ischemia - blood - complications - genetics |
2 |
|
nasopharyngeal neoplasms - physiopathology - radiotherapy |
2 |
|
nasopharyngeal neoplasms - radiotherapy |
2 |
|
nasopharyugeal carcinoma |
2 |
|
neoplasm proteins - metabolism |
2 |
|
nerve compression syndromes - complications |
2 |
|
niddm |
2 |
|
nitroglycerin - pharmacology |
2 |
|
non-insulin-dependent diabetes mellitus |
2 |
|
normocholesterolemic tendon xanthomas |
2 |
|
novel splicing mutation |
2 |
|
obesity - epidemiology - etiology - metabolism |
2 |
|
obesity - epidemiology - etiology - physiopathology |
2 |
|
obesity - etiology |
2 |
|
obesity - metabolism |
2 |
|
obesity - metabolism - pathology |
2 |
|
oculomotor muscles |
2 |
|
optic nerve - physiopathology |
2 |
|
oral diabetes insipidus |
2 |
|
orbital diseases |
2 |
|
organ specificity - physiology |
2 |
|
oryza sativa |
2 |
|
osteoporosis - etiology - urine |
2 |
|
ovary - physiology |
2 |
|
oxidation-reduction |
2 |
|
p53 |
2 |
|
pancreatectomy |
2 |
|
pancreatic neoplasms - blood - diagnosis |
2 |
|
pancreatic neoplasms - complications - secretion - surgery |
2 |
|
paraganglioma - metabolism - pathology |
2 |
|
parathyroidectomy - methods - statistics & numerical data |
2 |
|
peptide phi - metabolism |
2 |
|
phaeochromocytoma |
2 |
|
pharmacodynamics |
2 |
|
pharmacological intervention |
2 |
|
phenotype |
2 |
|
pheochromocytoma - complications |
2 |
|
pheochromocytoma - complications - diagnosis - surgery |
2 |
|
pheochromocytoma - metabolism - pathology |
2 |
|
phosphoproteins - genetics |
2 |
|
pituitary gland - pathology |
2 |
|
pituitary gland, anterior - chemistry |
2 |
|
pituitary gland, anterior - metabolism |
2 |
|
pituitary gland, anterior - physiology |
2 |
|
pituitary neoplasms - complications - secretion |
2 |
|
pituitary neoplasms - diagnosis - secretion |
2 |
|
pituitary tumour |
2 |
|
plasmids |
2 |
|
point mutation |
2 |
|
polymerase chain reaction - methods |
2 |
|
polymorphism, genetic - genetics |
2 |
|
positive-pressure respiration |
2 |
|
positron-emission tomography and computed tomography |
2 |
|
probability |
2 |
|
progesterone - blood |
2 |
|
prolactin - blood |
2 |
|
propranolol - adverse effects |
2 |
|
protein folding |
2 |
|
protein precursors - genetics |
2 |
|
proteins - genetics - physiology - therapeutic use |
2 |
|
pyrroles - therapeutic use |
2 |
|
radiation therapy |
2 |
|
rat |
2 |
|
rats, inbred strains |
2 |
|
receptors, cholinergic - immunology |
2 |
|
receptors, glucocorticoid - genetics |
2 |
|
receptors, immunologic - genetics |
2 |
|
receptors, neuropeptide - drug effects |
2 |
|
receptors, pituitary hormone-regulating hormone - drug effects |
2 |
|
receptors, scavenger |
2 |
|
references (35) view in table layout |
2 |
|
renal failure |
2 |
|
repetitive sequences, nucleic acid |
2 |
|
resting metabolic rate |
2 |
|
rhabdomyolysis-etiology |
2 |
|
risk |
2 |
|
risk reduction behavior |
2 |
|
ritonavir - adverse effects - pharmacology |
2 |
|
rna splicing |
2 |
|
rna, messenger - analysis |
2 |
|
rna, messenger - drug effects - metabolism |
2 |
|
scavenger receptor |
2 |
|
scavenger receptors, class a |
2 |
|
scavenger receptors, class b |
2 |
|
sexual dimorphism |
2 |
|
simvastatin - administration & dosage - adverse effects |
2 |
|
single-blind method |
2 |
|
sleep apnea |
2 |
|
sleep apnea, obstructive - blood - complications - therapy |
2 |
|
sleep apnea, obstructive - complications - epidemiology - physiopathology |
2 |
|
small dense low density lipoprotein |
2 |
|
somatostatin - analogs & derivatives - therapeutic use |
2 |
|
somatostatin - blood |
2 |
|
spermatogenesis |
2 |
|
spermatogenesis - drug effects |
2 |
|
steroid hydroxylases - genetics |
2 |
|
sterol 27-hydroxylase |
2 |
|
stimulation, chemical |
2 |
|
subtotal thyroidectomy |
2 |
|
testicular volume |
2 |
|
testosterone - blood - metabolism |
2 |
|
therapeutic target |
2 |
|
thyroid gland - metabolism |
2 |
|
thyroid gland - radiation effects |
2 |
|
thyroid hormone |
2 |
|
thyroid hormones - physiology |
2 |
|
thyrotropin - blood |
2 |
|
thyroxine - analysis |
2 |
|
tissue distribution |
2 |
|
total thyroidectomy |
2 |
|
transcription factors - genetics |
2 |
|
triglycerides - antagonists & inhibitors - blood |
2 |
|
triglycerides - biosynthesis - blood |
2 |
|
triiodothyronine - blood |
2 |
|
tumor markers, biological - metabolism |
2 |
|
two-hybrid system techniques |
2 |
|
type ii diabetes |
2 |
|
uraemia |
2 |
|
urotensin |
2 |
|
vascular diseases - blood - etiology - prevention & control |
2 |
|
vascular risks |
2 |
|
vasoactive intestinal peptide |
2 |
|
vasoactive intestinal peptide - genetics |
2 |
|
vasoactive peptides |
2 |
|
vasoconstriction |
2 |
|
vasodilation - drug effects |
2 |
|
vasodilation - physiology |
2 |
|
vasodilator agents - pharmacology |
2 |
|
vegetables |
2 |
|
vena cava, inferior |
2 |
|
voluntary health agencies |
2 |
|
world health organization |
2 |
|
x-linked adrenoleukodystrophy |
2 |
|
xanthomatosis, cerebrotendinous - genetics |
2 |
|
yeast 2-hybrid system |
2 |
|
45 devices |
1 |
|
abducens nerve |
1 |
|
abnormal telangiectasia |
1 |
|
acromegaly - blood - complications - drug therapy |
1 |
|
acromegaly - blood - drug therapy - physiopathology |
1 |
|
acromegaly - blood - radiotherapy |
1 |
|
adeno-associated virus |
1 |
|
adenoma - complications - radiography |
1 |
|
adenoma - complications - radiography - surgery |
1 |
|
adenoma - complications - surgery |
1 |
|
adenoma - secretion - therapy |
1 |
|
adrenal cortex neoplasms - complications - radiography - surgery |
1 |
|
adrenal gland neoplasms - blood - complications - radionuclide imaging |
1 |
|
adrenal gland neoplasms - chemistry - ethnology - pathology - physiopathology |
1 |
|
adrenal gland neoplasms - complications - radiography |
1 |
|
adrenal gland neoplasms - diagnosis |
1 |
|
adrenal glands |
1 |
|
adrenal glands - blood supply |
1 |
|
adrenal masses |
1 |
|
adrenocorticotropic hormone - blood |
1 |
|
adrenocorticotropic hormone - deficiency |
1 |
|
afferent nerve |
1 |
|
afferent pathways - physiology |
1 |
|
aging - physiology |
1 |
|
aldosterone - blood |
1 |
|
aldosteronoma, adrenal |
1 |
|
anti-bacterial agents - therapeutic use |
1 |
|
antihypertensive agents - therapeutic use |
1 |
|
aortography |
1 |
|
autoanalysis - instrumentation |
1 |
|
autopsy |
1 |
|
beta-thalassemia - complications |
1 |
|
biological markers - analysis |
1 |
|
biopsy |
1 |
|
blood flow |
1 |
|
blood specimen collection - methods |
1 |
|
body composition - drug effects |
1 |
|
bone and bones - pathology |
1 |
|
bone marrow scintigraphy |
1 |
|
bone neoplasms - complications |
1 |
|
brain - pathology |
1 |
|
brain - pathology - radiation effects - radiography |
1 |
|
brain - radiography |
1 |
|
brain diseases - blood - diagnosis |
1 |
|
brain-pathology |
1 |
|
calcium - blood |
1 |
|
capsaicin - administration & dosage |
1 |
|
carcinoma - radiotherapy |
1 |
|
carcinoma, papillary - pathology |
1 |
|
carcinoma, squamous cell - radiotherapy |
1 |
|
cause of death |
1 |
|
cerebral cortex |
1 |
|
cerebral cortex - metabolism - physiology |
1 |
|
cerebral hemorrhage - etiology - pathology |
1 |
|
cerebrovascular disorders - etiology - pathology |
1 |
|
chi-square distribution |
1 |
|
chromogranin |
1 |
|
chromogranins - analysis |
1 |
|
chronic disease |
1 |
|
clinical trials as topic |
1 |
|
combined modality therapy |
1 |
|
controlled clinical trials as topic |
1 |
|
coronary disease - epidemiology - prevention & control |
1 |
|
corticotropin-releasing hormone - pharmacology |
1 |
|
cranial irradiation - adverse effects |
1 |
|
cranial nerve diseases - etiology |
1 |
|
delayed radionecrosis |
1 |
|
dependovirus - genetics |
1 |
|
diabetes mellitus - genetics - therapy |
1 |
|
diabetes mellitus, experimental - therapy |
1 |
|
diabetes mellitus, type 1 - blood - drug therapy |
1 |
|
diabetes mellitus, type 1 - ethnology - genetics - immunology |
1 |
|
diabetes mellitus, type 1 - physiopathology |
1 |
|
diabetes mellitus, type 1 - therapy |
1 |
|
diabetes mellitus, type 2 |
1 |
|
diabetes mellitus, type 2 - complications |
1 |
|
diabetes mellitus, type 2 - drug therapy - epidemiology |
1 |
|
diabetes mellitus, type 2 - drug therapy - ethnology - metabolism - physiopathology |
1 |
|
diabetes mellitus, type 2 - therapy |
1 |
|
diabetic angiopathies - drug therapy |
1 |
|
diabetic angiopathies - epidemiology |
1 |
|
diabetic angiopathies - epidemiology - prevention & control |
1 |
|
diabetic control |
1 |
|
diabetic nephropathies - drug therapy - ethnology - metabolism - physiopathology |
1 |
|
diabetic nephropathies - epidemiology |
1 |
|
diabetic nephropathies - physiopathology - prevention & control |
1 |
|
diabetic neuropathies - epidemiology |
1 |
|
diabetic retinopathy - blood |
1 |
|
diabetic retinopathy - diagnosis - epidemiology |
1 |
|
diabetic retinopathy - epidemiology |
1 |
|
disease-free survival |
1 |
|
dna, neoplasm - genetics |
1 |
|
dopamine agonists. |
1 |
|
drug administration schedule |
1 |
|
drug therapy |
1 |
|
duodenum - drug effects - innervation - physiology |
1 |
|
duodenum - metabolism |
1 |
|
electrocardiography |
1 |
|
electrolytes - blood |
1 |
|
endocrine gland neoplasms - blood - diagnosis - secretion |
1 |
|
endocrine gland neoplasms - metabolism |
1 |
|
endophthalmitis - diagnosis - drug therapy - microbiology |
1 |
|
epinephrine - blood |
1 |
|
erythrocyte sodium‐potassium atpase |
1 |
|
erythrocytes - enzymology |
1 |
|
evaluation studies as topic |
1 |
|
extramedullary haemopoiesis |
1 |
|
fabp4 |
1 |
|
galactorrhea - complications |
1 |
|
genes, dominant |
1 |
|
genes, homeobox - genetics |
1 |
|
genes, recessive |
1 |
|
genetic markers |
1 |
|
glomerular filtration rate |
1 |
|
glucagon - metabolism |
1 |
|
glucagonoma - metabolism |
1 |
|
glucocorticoids - pharmacology - physiology |
1 |
|
goiter - ethnology - immunology |
1 |
|
gonadotropin-releasing hormone - pharmacology |
1 |
|
gonadotropins - deficiency |
1 |
|
graves disease - genetics |
1 |
|
growth hormone - adverse effects - therapeutic use |
1 |
|
growth hormone - deficiency |
1 |
|
growth hormone - deficiency - secretion |
1 |
|
growth hormone-releasing hormone - pharmacology |
1 |
|
growth hormone-releasing hormone - physiology |
1 |
|
hand - innervation - physiology |
1 |
|
haploidy |
1 |
|
hematopoiesis, extramedullary |
1 |
|
hemoglobins - metabolism |
1 |
|
hepatocytes - cytology |
1 |
|
hif-1α |
1 |
|
histological variants |
1 |
|
hla antigens - genetics |
1 |
|
hla-a antigens |
1 |
|
hla-b antigens |
1 |
|
hla-dq alpha-chains |
1 |
|
hla-dq antigens - genetics |
1 |
|
hla-dq beta-chains |
1 |
|
hormones, ectopic - blood |
1 |
|
human growth hormone - blood - drug effects - secretion |
1 |
|
hydrochloric acid - administration & dosage - pharmacology |
1 |
|
hydrocortisone - blood |
1 |
|
hydrocortisone - secretion |
1 |
|
hyperaldosteronism - etiology |
1 |
|
hyperemia - chemically induced - physiopathology |
1 |
|
hyperglycemia - prevention & control |
1 |
|
hyperparathyroidism - blood - complications - epidemiology - surgery |
1 |
|
hyperprolactinaemia |
1 |
|
hyperprolactinemia |
1 |
|
hyperprolactinemia - drug therapy |
1 |
|
hyperprolactinemia - etiology |
1 |
|
hypertension - etiology |
1 |
|
hypertension, renovascular |
1 |
|
hypertension, renovascular - etiology |
1 |
|
hyperthyroidism - blood |
1 |
|
hyperthyroidism - complications |
1 |
|
hypnotics and sedatives |
1 |
|
hypocalcemia - etiology |
1 |
|
hypoglycemia - etiology |
1 |
|
hypoglycemic agents - adverse effects - therapeutic use |
1 |
|
hypokalemia - complications - metabolism |
1 |
|
hypokalemic periodic paralysis |
1 |
|
hypopituitarism - blood - etiology - pathology |
1 |
|
hypopituitarism - congenital |
1 |
|
hypopituitarism - etiology |
1 |
|
hypothalamo-hypophyseal system - physiopathology |
1 |
|
hypothalamo-hypophyseal system - radiation effects |
1 |
|
hypothalamo-hypophyseal-system-radiation-effects |
1 |
|
hypothalamus - chemistry - physiology |
1 |
|
hypothalamus - pathology |
1 |
|
hypothyroidism - metabolism |
1 |
|
incidentaloma |
1 |
|
infant |
1 |
|
injections, subcutaneous |
1 |
|
insulin - analysis |
1 |
|
insulin - genetics - metabolism |
1 |
|
insulin-like growth factor i - analysis - drug effects - secretion |
1 |
|
insulin-like growth factor-1 |
1 |
|
insulin-secreting cells - cytology |
1 |
|
insulinoma - complications |
1 |
|
intestinal mucosa - drug effects |
1 |
|
intestine |
1 |
|
intracerebral hemorrhage |
1 |
|
ischemia/reperfusion |
1 |
|
kidney - drug effects - physiopathology |
1 |
|
kidney failure, chronic - prevention & control |
1 |
|
knee - pathology |
1 |
|
lanreotide autogel |
1 |
|
liver - enzymology |
1 |
|
lumbar vertebrae - pathology |
1 |
|
lymphatic metastasis |
1 |
|
mesenteric artery, superior - drug effects |
1 |
|
metanephrine - urine |
1 |
|
metformin - therapeutic use |
1 |
|
midazolam |
1 |
|
midazolam - adverse effects |
1 |
|
mitogens - genetics |
1 |
|
monitoring, physiologic |
1 |
|
multiple endocrine neoplasia type 2a - genetics - prevention & control |
1 |
|
multiple endocrine neoplasia type 2b |
1 |
|
multiple endocrine neoplasia type 2b - diagnosis - genetics - surgery |
1 |
|
naloxone - pharmacology |
1 |
|
nasopharyngeal-neoplasms-radiotherapy |
1 |
|
necrosis |
1 |
|
neoplasm invasiveness |
1 |
|
neoplasm recurrence, local - pathology |
1 |
|
neoplasms, multiple primary - complications |
1 |
|
neurofibromatoses - complications |
1 |
|
neurofibromatosis |
1 |
|
neuron-specific enolase |
1 |
|
neuropathy |
1 |
|
non-insulin dependent diabetes mellitus |
1 |
|
norepinephrine - blood |
1 |
|
nucleic acid hybridization |
1 |
|
nutrition disorders - drug therapy |
1 |
|
octreotide - administration & dosage - therapeutic use |
1 |
|
oncogene proteins |
1 |
|
oncogene proteins - genetics |
1 |
|
optic disk - radiography |
1 |
|
optic nerve - abnormalities |
1 |
|
osmolar concentration |
1 |
|
osteosarcoma - complications |
1 |
|
oval stem cells |
1 |
|
pancreas - metabolism |
1 |
|
pancreatic neoplasms - complications |
1 |
|
pancreatic neoplasms - diagnosis |
1 |
|
pancreatic neoplasms - metabolism |
1 |
|
papillary carcinoma |
1 |
|
paralyses, familial periodic - complications - metabolism |
1 |
|
paralysis - etiology |
1 |
|
paraneoplastic endocrine syndromes - diagnosis |
1 |
|
parathyroid glands - surgery |
1 |
|
parathyroid neoplasms - complications - surgery |
1 |
|
pdx-1 |
1 |
|
peptide fragments - pharmacology |
1 |
|
peptide histidine isoleucine |
1 |
|
peptides, cyclic - administration and dosage - adverse effects |
1 |
|
petrosal sinus sampling |
1 |
|
pheochromocytoma - chemistry - ethnology - pathology - physiopathology |
1 |
|
pheochromocytoma - complications - diagnosis - secondary - surgery |
1 |
|
phosphopyruvate hydratase - analysis |
1 |
|
pituitary function tests |
1 |
|
pituitary gland - chemistry - physiology |
1 |
|
pituitary gland - cytology - metabolism |
1 |
|
pituitary gland - drug effects - metabolism |
1 |
|
pituitary gland - metabolism - physiology |
1 |
|
pituitary gland - radiation effects |
1 |
|
pituitary gland - secretion |
1 |
|
pituitary gland, anterior - drug effects - metabolism |
1 |
|
pituitary hormones - secretion |
1 |
|
pituitary hormones, anterior - blood |
1 |
|
pituitary irradiation - adverse effects |
1 |
|
pituitary neoplasms |
1 |
|
pituitary neoplasms - diagnosis |
1 |
|
pituitary neoplasms - secretion - therapy |
1 |
|
ploidies |
1 |
|
portal vein |
1 |
|
postoperative complications - etiology |
1 |
|
posttranslational processing |
1 |
|
prolactin |
1 |
|
prolactin - blood - metabolism |
1 |
|
prolactin - blood - secretion |
1 |
|
prolactin - metabolism |
1 |
|
prolactin - secretion |
1 |
|
propylthiouracil - pharmacology |
1 |
|
proteinuria |
1 |
|
proteinuria - prevention & control |
1 |
|
proto-oncogene proteins - genetics |
1 |
|
radiation injuries - complications |
1 |
|
radiation injuries - etiology |
1 |
|
radiation-injuries-etiology |
1 |
|
radiation-injuries-surgery |
1 |
|
radiography, interventional |
1 |
|
radiopharmaceuticals - diagnostic use |
1 |
|
radiotherapy |
1 |
|
radiotherapy dosage |
1 |
|
radiotherapy, high-energy - adverse effects |
1 |
|
radiotherapy-adverse-effects |
1 |
|
random allocation |
1 |
|
receptor protein-tyrosine kinases - genetics |
1 |
|
receptors, opioid - drug effects |
1 |
|
receptors, somatostatin - metabolism |
1 |
|
renal artery obstruction - complications - radiography |
1 |
|
renin-angiotensin system - drug effects |
1 |
|
research design |
1 |
|
retinopathy |
1 |
|
retroviridae |
1 |
|
rna, messenger - biosynthesis |
1 |
|
seizures - etiology |
1 |
|
self care |
1 |
|
self medication |
1 |
|
self-monitoring of blood glucose |
1 |
|
septum pellucidum - abnormalities |
1 |
|
sodium-potassium-exchanging atpase - metabolism |
1 |
|
somatostatin - administration and dosage - adverse effects - analogs and derivatives |
1 |
|
somatostatin analogue |
1 |
|
somatostatin receptor |
1 |
|
stem cells - cytology |
1 |
|
stenosis, renal artery |
1 |
|
sulfonylurea compounds - therapeutic use |
1 |
|
sympathetic nervous system - drug effects |
1 |
|
synaptophysin |
1 |
|
synaptophysin - analysis |
1 |
|
technetium tc 99m aggregated albumin - diagnostic use |
1 |
|
temporal-lobe-radiation-effects |
1 |
|
tendons |
1 |
|
thalassaemia |
1 |
|
thyroid |
1 |
|
thyroid diseases - blood - enzymology |
1 |
|
thyroid hormones |
1 |
|
thyroid neoplasms - pathology |
1 |
|
thyroid-stimulating hormone |
1 |
|
thyroiditis, autoimmune - ethnology - immunology |
1 |
|
thyrotoxicosis - blood |
1 |
|
thyrotoxicosis - complications - metabolism |
1 |
|
thyrotoxicosis/hyperthyroidism |
1 |
|
thyrotropin |
1 |
|
thyrotropin - physiology |
1 |
|
thyrotropin-releasing hormone - pharmacology |
1 |
|
thyrotropin-releasing hormone - physiology |
1 |
|
thyroxine |
1 |
|
thyroxine - blood |
1 |
|
thyroxine - pharmacology |
1 |
|
thyroxine - physiology |
1 |
|
tomography, emission-computed, single-photon - methods |
1 |
|
torsade de pointes |
1 |
|
torsades de pointes |
1 |
|
triac |
1 |
|
triiodothyronine - pharmacology |
1 |
|
trisaccharides - adverse effects - therapeutic use |
1 |
|
tuberculosis, meningeal - complications |
1 |
|
urinary tract infections - diagnosis - drug therapy |
1 |
|
vanilmandelic acid - urine |
1 |
|
vasoactive intestinal peptide - analysis - physiology |
1 |
|
vasoactive intestinal peptide - metabolism |
1 |
|
vasoactive intestinal peptide - physiology |
1 |
|
veins |
1 |
|
xanthomatosis - blood - diagnosis |
1 |
|
xanthomatosis. |
1 |
